Acne: Rambazole Can Be A Good Medication Against Acne In Future

A study with Rambazole, a novel retinoic acid
metabolism-blocking agent (RAMBA), determined that 94 per cent
of subjects -with moderate-to-severe acne treated with 1 mg of
oral Rambazole once daily for 12 consecutive weeks- experienced
reduction in total acne lesion count of more than 50 per cent
and 35 per cent were considered "cleared or almost cleared.

This study points to the production of this medication on
future, since Barrier Therapeutics, Inc. reported positive Phase
2a data for its oral formulation of Rambazole (TM) in the
treatment of moderate to severe acne and positive biological
activity data for its topical formulation of this product.

Experts explain that a subject must have had more than 90 per
cent reduction in total lesion count to be considered "cleared
or almost cleared". According to their report, inflammatory and
non-inflammatory lesions responded equally well to treatment.
There were no serious effects related to the treatment with this
new component. Only some patients of the group in study
experienced dryness of skin and lips as non-serious side effects.

Geert Cauwenbergh, Ph.D., Chairman and Chief Executive Officer
of Barrier Therapeutics, Inc. explained that "these positive
Phase 2a results indicate that oral Rambazole is active in
moderate to severe inflammatory acne, and that depending on the
outcome of future, full scale clinical trials, this drug may one
day fill the need for safe and effective oral treatments for
moderate and severe acne. These results further build on our
previously announced promising clinical data for oral Rambazole
for psoriasis".